Drug Profile
AC 084
Alternative Names: AC-084Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in United Kingdom (PO)
- 10 Apr 2018 Actelion terminates a phase I trial in healthy volunteers in United Kingdom due to difficulty in enrolment in its part C (NCT02905253)
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals